Other Events ·
Skye Bioscience, Inc. received approval from Nasdaq to transfer its common stock listing from the Nasdaq Global Market…
SKYESkye Bioscience, Inc.
Skye Bioscience, Inc. received approval from Nasdaq to transfer its common stock listing from the Nasdaq Global Market to the Nasdaq Capital Market effective June 23, 2026, due to failing to meet the $10,000,000 minimum stockholders' equity requirement. The company's initial 180-day compliance period to resolve a separate minimum bid price deficiency (requiring a close above $1.00 per share) will continue through September 14, 2026, following the transfer. Skye Bioscience, Inc. is a biotechnology company focused on metabolic and metabolic-related diseases.